The Post-EBMT VJSessions from VJHemOnc
Join VJHemOnc for an exclusive session with Christian Chabannon, Nico Gagelmann, Zinaida Perić & Eolia Brissot reviewing key updates from…
Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies
Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…
VJSessions: Highlights from the 3rd European EBMT-EHA CAR T-cell Meeting Nurses Programme
A session with experts Erik Aerts, John Murray, Michelle Kenyon & Rose Ellard who cover key areas discussed during the…
The Lymphoma Sessions: UK post-ASH 2020 discussion
A session with UK experts Graham Collins and Wendy Osborne, who discuss the key lymphoma highlights presented at ASH 2020.
The Transplant Sessions: post-ASH 2020 roundtable discussion
A session with experts Bruce Levine and Christian Chabannon, who discuss the exciting updates in transplantation and cell therapy from…
The Lymphoma Sessions: post-ASH 2020 roundtable discussion
A session with experts Stephen Ansell and Graham Collins, who discuss the latest lymphoma updates from ASH 2020.
The VJ Sessions:
Roundtable discussions with leading experts in hemonc
VJHemOnc brings you roundtable discussions with leading hematological experts in myeloma, AML, CLL, ALL, lymphoma, MDS and MPNs.
SOHO Italy 2020 Virtual Meeting
VJHemOnc is proud to present the SOHO Italy 2020 Virtual Meeting, which took place on the 22nd-24th of September 2020.
FDA approves brexucabtagene autoleucel for MCL
The Food and Drug Administration (FDA) has approved a new path of treatment for patients with mantle cell lymphoma (MCL)…
EHA 2020 Top Picks
VJHemOnc are excited to present late-breaking abstracts and key trial updates announced at this year’s virtual EHA meeting!
FDA approve ibrutinib and rituximab combination for CLL
Following positive results gleaned from the E1912 trial (NCT02048813), the U.S. Food and Drug Administration (FDA) has expanded the indication…
Radioimmunotherapy agent improves progression-free survival of NHL patients in real-world setting
A study presented during the 2020 American Society of Clinical Oncology and Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium,…
Positive top-line results for pivotal phase III FLASH trial in CTCL
The treatment options for cutaneous T-cell lymphoma (CTCL) are currently limited, with research ongoing in several clinical trials. SGX301 (synthetic…
Brentuximab vedotin may hold improved outcomes in frontline stage III/IV classical Hodgkin lymphoma
Updated results from the ECHELON-1 study (NCT01712490) suggest the combination of brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) may…